AYTU BIOPHARMA, INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
AYTU BIOPHARMA, INC (AYTU) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $66.18 thousand for the 9-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2021-05-17
- AYTU BIOPHARMA, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $23.10K.
- AYTU BIOPHARMA, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $22.64K.
- AYTU BIOPHARMA, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $20.44K, a 95.05% decline year-over-year.
- AYTU BIOPHARMA, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was -$20.03K.
- AYTU BIOPHARMA, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $334.89K.
- AYTU BIOPHARMA, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $23.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | $45.74K derived: sum of 2 quarters · filed 2021-05-17 | $66.18K 10-Q · filed 2021-05-17 | $46.15K derived: sum of 4 quarters · filed 2021-05-17 | |
| 2020-12-31 | $22.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $43.08K 10-Q · filed 2021-02-11 | $23.05K derived: sum of 3 quarters · filed 2021-02-11 | -$34.71K derived: sum of 4 quarters · filed 2021-05-17 | |
| 2020-09-30 | $20.44K 10-Q · filed 2020-11-12 | $404.00 derived: sum of 2 quarters · filed 2020-11-12 | -$57.36K derived: sum of 3 quarters · filed 2021-05-17 | -$57.36K derived: sum of 4 quarters · filed 2021-05-17 | |
| 2020-06-30 | -$20.03K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | -$77.80K derived: sum of 2 quarters · filed 2021-05-17 | -$77.80K derived: sum of 3 quarters · filed 2021-05-17 | $334.89K 10-K · filed 2020-10-06 | |
| 2020-03-31 | -$57.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | -$57.76K derived: sum of 2 quarters · filed 2021-05-17 | $354.93K 10-Q · filed 2021-05-17 | $354.93K derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $412.69K 10-Q · filed 2021-02-11 | $374.57K 10-Q · filed 2020-02-14 | $412.69K derived: sum of 3 quarters · filed 2021-02-11 | $412.69K derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-09-30 | $412.69K 10-Q · filed 2020-11-12 | $412.69K derived: sum of 2 quarters · filed 2020-11-12 | $412.69K derived: sum of 3 quarters · filed 2020-11-12 | $412.69K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $0.00 derived: sum of 2 quarters · filed 2020-10-06 | $0.00 derived: sum of 3 quarters · filed 2020-10-06 | $0.00 10-K · filed 2020-10-06 | |
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $0.00 10-Q · filed 2020-05-15 | ||
| 2018-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $0.00 10-Q · filed 2020-02-14 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |